Abcalis® product portfolio also features anti-SARS-CoV-2 recombinant sequence defined, monoclonal antibodies made by animal-free methods.

We believe that recombinant primary antibodies can deliver a significant improvement over the current standard testing procedure of utilizing RT-PCR testing. Given that RT-PCR tests are complex, cost-intensive and time-consuming, the tests are not truly suitable for the real-time control of epidemiological measures due to the time delay from taking the sample until getting a result. Abcalis provides antibodies against S1-, S1+S2-, RBD- as well as N-protein.

Regarding antigen based tests, apart from other factors these tests are also partially based on the use of an antibody validated for binding to heat-inactivated virus particles.

But the assumption that antibody binding against heat-inactivated virus particles is similar to binding to the native viral protein may underestimate the risk of false positive results.
The solutions from and with Abcalis® are therefore qualified to meet regulatory standards and criteria even in the long term, as is the standard with all Abcalis® products, since they are all completely sequence defined, implying their unlimited long-term availability and always identical test results. This should allows for a much lower unspecific binding reactivity in many assays compared to animal based products.

Currently, we are offering a variety of different clones with specificities to the S1-, S1+S2-, RBD- as well as N-protein and work with them in different projects for different applications.